Swiss CDMO Lonza has announced the appointment of Samanta Cimitan as its new Chief Commercial Officer (CCO), a newly created role that will take effect by January 1, 2027. The move is part of Lonza's 'One Lonza' strategy, which aims to streamline customer engagement and harmonize commercial operations across its three business platforms.
Cimitan, currently CEO of the Celonic Group, brings extensive leadership experience in the contract development and manufacturing organization (CDMO) sector. She previously spent nearly 13 years at Lonza in commercial and strategy roles, including Vice President of Group Operations Strategy. Her return is expected to strengthen Lonza's focus on strategic account management, global marketing, and commercial excellence.
Wolfgang Wienand, Lonza's CEO, emphasized the importance of the role in 'making the full power of the Lonza Engine work for our partners.' He noted that Cimitan's deep CDMO expertise and firsthand knowledge of Lonza will help build trusted partnerships and create value across the entire development and manufacturing journey.
The creation of the CCO position reflects Lonza's response to the growing complexity of the pharmaceutical outsourcing market. By consolidating commercial leadership, Lonza aims to provide a seamless experience for customers seeking its end-to-end services, from drug development to large-scale manufacturing. This strategic alignment is critical as the CDMO industry faces increasing demand for integrated solutions and faster time-to-market.
Industry analysts view this appointment as a signal of Lonza's commitment to customer-centric innovation. With a global team of approximately 20,000 employees and half-year 2026 sales of CHF 3.4 billion, Lonza is positioning itself to better serve pharma and biotech companies worldwide. The new role is designed to make it easier for customers to access Lonza's full range of capabilities, potentially accelerating the delivery of life-saving therapies.
Cimitan's track record at Celonic, where she led the company's transformation into a focused biologics CDMO, suggests she will bring a pragmatic approach to commercial strategy. Her experience in operational execution and regulatory readiness will be vital as Lonza continues to expand its services.
The appointment also underscores a broader trend in the CDMO industry: the shift toward more integrated, customer-focused business models. As drug developers seek partners who can handle complex manufacturing processes, companies like Lonza are investing in leadership structures that prioritize commercial agility and cross-functional collaboration.
For more information on Lonza's strategic initiatives, visit Lonza's website. The original announcement can be accessed via NewMediaWire.
